Pluvicto Ad

Why TheranosticTrials.org?

The leading global platform for radiopharmaceutical & molecular imaging clinical trials

Global Reach

We are uniquely positioned at the heart of Theranostics.

Increasing Awareness

We're dedicated to increasing awareness about Theranostics and it's potential.

Fostering Engagement

We encourage active participation in the Theranostics community.

Building Connections

We connect physicians, clinics, and patients with Theranostic opportunities.

Comprehensive Resources

Access a complete list of cancer Theranostic Trials and educational materials.

Advancing the Field

We collaborate with key opinion leaders to push Theranostics forward.

Our Ultimate Goal

Provide more hope to cancer patients everywhere!


Navigating Tips

Pick Your Path


Stats

Theranostic Trials Global Ecosystem

View All


Isotopes

View details about the isotopes used in the trials listed on our site!

Learn more
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
SAMARIUM-153
Radioisotope: Sm153
Theranostic Role: Therapeutic
T1/2 (Half-Life): 1.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Max 808 keV Gamma: 103 keV (28%)
Range: 0.6 mm
Decay Daughters: Eu153 (Stable)
Status: FDA Approval: QUADRAMET® (1997)
TECHNETIUM-99m
Radioisotope: Tc-99m
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 6 Hours
Decay Mode: GAMMA
Energy: 140 keV (89.1%)
Range: N/A
Decay Daughters: Tc99
Status: FDA Approval: First in 1980’s

DI Badge

Distinguished Investigator

A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.

Michael Gorin, MD

Dr. Michael Gorin is an associate professor of urology at the Icahn School of Medicine at Mount Sinai. Dr. Gorin is widely recognized for his work studying the use of molecular imaging in the diagnosis and management of urologic malignancies. To his credit, Dr. Gorin was part of the first clinical team to study PSMA-targeted PET imaging of prostate cancer with PYLARIFY (18F-DCFPyL). Additionally, he played an integral role in the design and conduct of two multicenter clinical trials that led to the approval of this novel PET radiotracer by the United States Food and Drug Administration. Since its approval in May 2021, PYLARIFY has been used to image over 100,000 men with prostate cancer. Dr. Gorin has also made significant contributions to the field of urology through his research on prostate cancer screening, active surveillance, and focal therapy. More recently, Dr. Gorin’s academic focus has shifted towards the implementation of artificial intelligence tools to improve the care of urologic patients. This work includes developing computer vision tools to augment the diagnostic capabilities of existing radiology techniques. Additionally, he has developed expertise working with voice and text-based large language models. He has developed a variety of applications aimed at improving medical education, patient care, and physician efficiency. To date, Dr. Gorin has published over 300 scholarly articles in the medical literature. Additionally, he has contributed to multiple medical textbooks, including chapters in Campbell-Walsh-Wein Urology, The 5-Minute Urology Consult, and Gray's Anatomy. In July 2022, Dr. Gorin was named Editor-in-Chief of BJUI Compass, the open-access companion journal to the British Journal of Urology International. Dr. Gorin also serves on the editorial boards of several other journals including Urologic Oncology and the World Journal of Urology. Dr. Gorin has received numerous honors and awards for his scholarly work, including the Drs. Carl and Barbara Alving Endowed Award for Outstanding Biomedical Research from the University of Miami Miller School of Medicine and the William F. Rienhoff, Jr., M.D. Scholar Award from Johns Hopkins University School of Medicine. Dr. Gorin attended college at the University of Michigan, earning a Bachelor of Science in Cellular and Molecular Biology. He then attended medical school at the University of Miami Leonard M. Miller School of Medicine, where he graduated as an inductee to the Alpha Omega Alpha Honor Medical Society. Following medical school, Dr. Gorin completed a general surgery internship, urology residency, and fellowship in endoscopic and minimally invasive urology at the world-renowned James Buchanan Brady Urological Institute at Johns Hopkins University School of Medicine

Read More >>

See All Investigators

RLT Components

RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.

There are several Components to a RLT that are simply demonstrated in the truck diagram including:

  1. Cancer Targets
  2. Ligand (demonstrated as the Truck GPS set to find a specific Target)
  3. Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
  4. Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
  5. Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
  6. Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).

To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.

View RLT Components

Education


banana

Sponsors

blueearththerapeuticsltdportlandinvestmentcounselurotodayblueearthdiagnosticsltdadvancedacceleratorapplicationsbayertelixpharmaceuticalsfusionpharmaceuticalsincclaritypharmaceuticalscuriumpointbiopharmajanssenpharmaceuticalsratiotherapeuticsincartbionorthstarnucleusradiopharmaspagonanomedicalabradiopharmtheranosticsprostatecancerfoundationperspectivetherapeuticsinvenraconvergenttherapeuticsterrapowerisotopesnusanorlsradiopharmacieslantheusmedicalimaging
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468